Marzena Olesinska

List of Publications by Year
in descending order

93 papers	3,314 citations	304743 22 h-index	161849 54 g-index
93 all docs	93 docs citations	93 times ranked	4476 citing authors

#	Article	IF	Citations
1	Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation. International Journal of Molecular Sciences, 2022, 23, 5317.	4.1	3
2	Association study between immune-related miRNAs and mixed connective tissue disease. Arthritis Research and Therapy, 2021, 23, 19.	3.5	3
3	Impact and Possible Mechanism(s) of Adipose Tissue-Derived Mesenchymal Stem Cells on T-Cell Proliferation in Patients With Rheumatic Disease. Frontiers in Physiology, 2021, 12, 749481.	2.8	8
4	Modulation of T-Cell Activation Markers Expression by the Adipose Tissueâ€“Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases. Cell Transplantation, 2020, 29, 096368972094568.	2.5	10
5	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
6	Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritisâ€“From Research to Clinical Practice. Cells, 2020, 9, 1127.	4.1	51
7	The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus. Biomolecules, 2020, 10, 494.	4.0	7
8	Global miRNA and mRNA expression profiles identify miRNAâ€26aâ€2â€3pâ€dependent repression of IFN signature in systemic sclerosis human monocytes. European Journal of Immunology, 2020, 50, 1057-1066.	2.9	14
9	KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. Biomolecules, 2019, 9, 355.	4.0	13
10	IL-35, TNF-Î±, BAFF, and VEGF serum levels in patients with different rheumatic diseases. Reumatologia, 2019, 57, 145-150.	1.1	14
11	Neutrophil extracellular traps generation and degradation in patients with granulomatosis with polyangiitis and systemic lupus erythematosus. Autoimmunity, 2019, 52, 126-135.	2.6	20
12	Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Quality of Life Research, 2019, 28, 3347-3354.	3.1	29
13	Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia, 2019, 57, 257-263.	1.1	12
14	The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases. Cells, 2019, 8, 1659.	4.1	21
15	Polyautoimmunity in rheumatological conditions. International Journal of Rheumatic Diseases, 2019, 22, 386-391.	1.9	32
16	Lack of association between rheumatoid arthritis and genetic variants rs10889677, rs11209026 and rs2201841 of IL-23R gene. Medicina ClÃnica, 2018, 151, 191-195.	0.6	6
17	HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a caseâ€“control study. Inflammation Research, 2018, 67, 423-433.	4.0	7
18	Subgroups of SjÃ¶grenâ€™s syndrome patients categorised by serological profiles: clinical and immunological characteristics. Reumatologia, 2018, 56, 346-353.	1.1	12

#	Article	IF	Citations
19	Differential diagnosis of idiopathic inflammatory myopathies in adults â€“ the first step when approaching a patient with muscle weakness. Reumatologia, 2018, 56, 307-315.	1.1	3
20	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia, 2018, 56, 203-211.	1.1	21
21	Lack of significant association between selected STAT3 polymorphisms and rheumatoid arthritis in the Polish population. Reumatologia, 2018, 56, 73-79.	1.1	1
22	Antimalarials â€“ are they effective and safe in rheumatic diseases?. Reumatologia, 2018, 56, 164-173.	1.1	65
23	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. Reumatologia, 2018, 56, 140-148.	1.1	7
24	Quality of life in systemic lupus erythematosus and its measurement. Reumatologia, 2018, 56, 45-54.	1.1	67
25	AB0775â€…Characteristics of patients with scleroderma (SSC) treated with various drugs in the clinical assessment and tgf Î² and il13 concentration in comparison to the healthy group. , 2018, , .		0
26	FRI0429â€…Distinct clinical and immunological picture of mctd patients with skin involvement. , 2018, , .		0
27	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
28	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
29	<scp>IL</scp>â€12B Gene Polymorphisms and <scp>IL</scp>â€12 p70 Serum Levels Among Patients with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2017, 85, 147-154.	2.7	15
30	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754
31	Epigenetics: The Future Direction in Systemic Sclerosis. Scandinavian Journal of Immunology, 2017, 86, 427-435.	2.7	11
32	THU0012â€…HLA-DBR1 alleles profile in patients with rheumatoid arthritis: relation to disease susceptibility and severity. , 2017, , .		0
33	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
34	03.15â€…Identification of novel micrornas in monocytes from rheumatoid arthritis and systemic sclerosis patients using next generation sequencing. , 2017, , .		0
35	AB1184â€…Educational needs of patients with rheumatic diseases receiving biologics. , 2017, , .		0
36	FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis. PLoS ONE, 2017, 12, e0172018.	2.5	6

#	Article	IF	Citations
37	Esophageal transit scintigraphy in systemic sclerosis. Reumatologia, 2016, 54, 251-255.	1.1	3
38	Rivaroxaban â€“ a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia, 2016, 3, 146-149.	1.1	29
39	Discrepancies in assessment of patients with rheumatoid arthritis and secondary SjÃ¶grenâ€™s syndrome by DAS28-ESR and DAS28-CRP. Central-European Journal of Immunology, 2016, 2, 188-194.	1.2	5
40	Capillaroscopy â€“ a role in modern rheumatology. Reumatologia, 2016, 54, 67-72.	1.1	71
41	RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2016, 17, 488.	4.1	3
42	Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. Reumatologia, 2016, 54, 296-305.	1.1	11
43	Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. Reumatologia, 2016, 54, 187-195.	1.1	6
44	Association of HLAâ€ÐRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. Hla, 2016, 87, 13-18.	0.6	24
45	AB0586â€…Predictors of Interstitial Lung Disease in 79 Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 1105.1-1105.	0.9	0
46	SAT0195â€…Early Nailfold Capillaroscopic Pattern Predominates in Patients with Mixed Connective Tissue Disease. Annals of the Rheumatic Diseases, 2016, 75, 738.3-738.	0.9	1
47	AB0275â€…Differences in The Clinical Evaluation of Joints in Patients with Rheumatoid Arthritis and Secondary SjÃ¶gren Syndrome. Annals of the Rheumatic Diseases, 2016, 75, 993.3-994.	0.9	0
48	AB0002â€…Genetic Variants in IL-17F, IL-23 and IL-23R in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.2-897.	0.9	0
49	AB0001â€…Genetic Variants in IL-12B and IL-27 in The Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 897.1-897.	0.9	0
50	Genetic Variants in <scp>IL</scp>â€12B and <scp>IL</scp>â€27 in the Polish Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Immunology, 2016, 84, 49-60.	2.7	21
51	Impact of the IL-17F, IL-23 and IL-23R on susceptibility and phenotype of systemic lupus erythematosus. Autoimmunity, 2016, 49, 373-382.	2.6	12
52	Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0160769.	2.5	32
53	Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems â€“ A cross-sectional study. Annals of Agricultural and Environmental Medicine, 2016, 23, 361-367.	1.0	8
54	Polyautoimmunity: aÂsignificant issue inÂconnective tissue diseases. Polish Archives of Internal Medicine, 2016, 126, 837-838.	0.4	0

#	Article	IF	Citations
55	TheÂinternal medicine in crisis: theÂanalysis of causes and proposed changes. Polish Archives of Internal Medicine, 2016, 126, 1068-1073.	0.4	0
56	Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques - a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness. Acta Cardiologica, 2015, 70, 169-175.	0.9	15
57	Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis B. Reumatologia, 2015, 6, 337-340.	1.1	1
58	TNF-308G/A polymorphism and risk of systemic lupus erythematosus in the Polish population. Modern Rheumatology, 2015, 25, 719-723.	1.8	9
59	Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatology International, 2015, 35, 385-392.	3.0	9
60	JHDM1D and HDAC1â€“3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Zeitschrift Fur Rheumatologie, 2015, 74, 902-910.	1.0	12
61	Association of the Smad3 and NFATc2 gene polymorphisms and their serum levels with susceptibility to rheumatoid arthritis in Polish cohorts. Clinical and Experimental Immunology, 2015, 179, 444-453.	2.6	8
62	IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease. Modern Rheumatology, 2015, 25, 487-489.	1.8	8
63	Genetic Polymorphisms of Foxp3 in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 170-180.	2.0	22
64	Genetic variants of DNMT3A and systemic lupus erythematosus susceptibility. Modern Rheumatology, 2015, 25, 96-99.	1.8	7
65	Levels of Antibodies against Human Heat Shock Protein (HSP) 60 in Patients with Glaucoma in Poland. Medical Science Monitor, 2015, 21, 828-832.	1.1	5
66	Recommendations for diagnosis and treatment Selected principles of proper education of women with rheumatic diseases in respect of pregnancy planning. Reumatologia, 2014, 1, 49-56.	1.1	2
67	Recommendations for diagnosis and treatment Recommendations for obstetric management and principles of cooperation between rheumatologists and obstetricians in systemic connective tissue disease patients. Reumatologia, 2014, 1, 38-48.	1.1	0
68	Optimism, pain coping strategies and pain intensity among women with rheumatoid arthritis. Reumatologia, 2014, 52, 166-171.	1.1	8
69	Fertility, pregnancy planning, and pharmacotherapy during the pregnancy, postpartum and breastfeeding period in patients with rheumatoid arthritis and other inflammatory arthropathies. Reumatologia, 2014, 52, 7-21.	1.1	2
70	Recommendations for diagnosis and treatment Fertility, pregnancy planning, and treatment during the pregnancy, postpartum and breastfeeding period in patients with antiphospholipid syndrome. Reumatologia, 2014, 1, 30-37.	1.1	0
71	Recommendations for diagnosis and treatment Fertility, pregnancy and breastfeeding in systemic lupus erythematosus patients. Reumatologia, 2014, 1, 22-29.	1.1	0
72	TheFCRL3â^'169T>C polymorphism might be associated with some autoantibody presence in patients with SLE in a Polish population. Modern Rheumatology, 2014, 24, 296-299.	1.8	6

#	Article	IF	Citations
73	Association of Single Nucleotide Polymorphisms in the <scp>IL</scp>27 Gene with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2014, 80, 298-305.	2.7	30
74	Vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus. Molecular Biology Reports, 2013, 40, 803-810.	2.3	49
75	Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus. Rheumatology International, 2013, 33, 1121-1125.	3.0	20
76	Single nucleotide polymorphism of CD40 region and the risk of systemic lupus erythematosus. Lupus, 2013, 22, 233-237.	1.6	13
77	Takayasu arteritis: is disease activity assessment possible?. Reumatologia, 2013, 2, 144-150.	1.1	1
78	Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus, 2012, 21, 927-933.	1.6	18
79	B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. Biologics: Targets and Therapy, 2012, 6, 347.	3.2	7
80	Contribution of STAT4 gene single-nucleotide polymorphism to systemic lupus erythematosus in the Polish population. Molecular Biology Reports, 2012, 39, 8861-8866.	2.3	23
81	Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatology International, 2012, 32, 639-643.	3.0	28
82	Prevalence of the NKG2D Thr72Ala polymorphism in patients with systemic lupus erythematosus. Molecular Biology Reports, 2012, 39, 1343-1347.	2.3	10
83	Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus, 2011, 20, 85-89.	1.6	18
84	ITGAM Arg77His Is Associated with Disease Susceptibility, Arthritis, and Renal Symptoms in Systemic Lupus Erythematosus Patients from a Sample of the Polish Population. DNA and Cell Biology, 2011, 30, 33-38.	1.9	17
85	Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clinical Rheumatology, 2010, 29, 605-613.	2.2	63
86	Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus, 2010, 19, 949-956.	1.6	134
87	Monocyte Chemoattractant Protein-1<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo>â˜’</mml:mo></mml:mrow></mml:math>2518 A/G Single Nucleotide Polymorphism Might Be Associated with Renal Disease and Thrombocytopenia of SLE. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	15
88	Target Therapies in Systemic Lupus Erythematosus: Current State of the Art. Mini-Reviews in Medicinal Chemistry, 2010, 10, 956-965.	2.4	7
89	Clinical manifestation of systemic lupus erythematosus in patients with antiribosomal P protein antibodies. Polish Archives of Internal Medicine, 2010, 120, 76-81.	0.4	6
90	Sarcoidosis: selected clinical cases. Polish Archives of Internal Medicine, 2009, 119, 514-517.	0.4	0

#	Article	IF	Citations
91	Current causes of death in systemic lupus erythematosus in Europe, 2000â€”2004: relation to disease activity and damage accrual. Lupus, 2007, 16, 309-317.	1.6	189
92	Evaluation of systemic lupus erythematosus activity during pregnancy. Polish Archives of Internal Medicine, 2007, 117, 312-316.	0.4	4
93	Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity, 2006, 39, 243-247.	2.6	51